LumiThera LT-300 granted CE mark for treating dry AMD

The European Union has granted a CE mark for the LT-300 light delivery system, a treatment device for dry age-related macular degeneration, LumiThera announced in a press release.

“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II clinical study in select European sites in the upcoming months,” Clark Tedford, PhD, LumiThera president and CEO, said in the release. “We are excited to be able to offer a safe and effective early-stage clinical intervention for patients with dry AMD.”

The LT-300 device uses photobiomodulation, which involves noninvasive light-emitting diodes for the treatment of ocular diseases.

The European Union has granted a CE mark for the LT-300 light delivery system, a treatment device for dry age-related macular degeneration, LumiThera announced in a press release.

“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II clinical study in select European sites in the upcoming months,” Clark Tedford, PhD, LumiThera president and CEO, said in the release. “We are excited to be able to offer a safe and effective early-stage clinical intervention for patients with dry AMD.”

The LT-300 device uses photobiomodulation, which involves noninvasive light-emitting diodes for the treatment of ocular diseases.